Economics
In the U.S., the price of cycloserine increased from $500 for 30 pills to $10,800 in 2015 after the Chao Center for Industrial Pharmacy and Contract Manufacturing changed ownership to Rodelis Therapeutics in August 2015.The price increase was rescinded after the previous owner, the Purdue University Research Foundation, which retained "oversight of the manufacturing operation" intervened and Rodelis returned the drug to an NGO of Purdue University. The foundation now will charge $1,050 for 30 capsules, twice what it charged before". Eli Lilly has been criticised for not ensuring that the philanthropic initiative continued. Due to US antitrust laws, however, no company may control the price of a product after it is outlicensed.In 2015, the cost in the United States was increased to US$3,150 a month and then decreased to US$1,050 per month. Research
There is some experimental evidence to suggest that D-cycloserine aids in learning by helping form stronger neural connections. It has been investigated as an aid to facilitate exposure therapy in people with PTSD and anxiety disorders as well as treatment with schizophrenia. In a clinical trial, a course of D-cycloserine combined with a single dose of ketamine was investigated for treatment resistant bipolar depression. When administered for 8 weeks after a ketamine infusion, cycloserine appeared to potentiate the antidepressant effects in all trial participants. References
External links
"Cycloserine". Drug Information Portal. U.S. National Library of Medicine.
The city was even dubbed Chissos "castle town," in reference to the capital cities of feudal lords who ruled Japan during the Edo period.The Chisso factory first started acetaldehyde production in 1932, with 210 tons that year. In 1951, production had jumped to 6,000 tons and eventually peaked at 45,245 tons in 1960. The factorys output historically amounted to between a quarter and a third of Japans total acetaldehyde production. The chemical reaction used to produce the acetaldehyde employed mercury sulfate as a catalyst. Starting in August 1951, the co-catalyst was changed from manganese dioxide to ferric sulfide. A side reaction of this catalytic cycle led to the production of a small amount (about 5% of the outflow) of the organic mercury compound methylmercury. As a result of the catalyst change, this highly toxic compound was released into Minamata Bay regularly between 1951 and 1968, when this production method was finally discontinued. 1956–1959
On 21 April 1956, a five-year-old girl was examined at Chissos factory hospital in Minamata. The physicians were puzzled by her symptoms: difficulty walking, difficulty speaking, and convulsions. Two days later, her younger sister also began to exhibit the same symptoms and she, too, was hospitalised. The girls mother informed doctors that her neighbours daughter was also experiencing similar problems. After a house-to-house investigation, eight further patients were discovered and hospitalised.